试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-06-21
Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion
编号:NCT02338466登记状态:入组前撤回企业 / 申办者:University Hospital Center of Martinique
药物 / 成分:rt-PA、tenecteplase
登记的停止原因(原文):Departure of the principal investigator and lack of succession
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-06-21
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
编号:NCT02630394登记状态:入组前撤回企业 / 申办者:University of Mississippi Medical Center
药物 / 成分:Azithromycin
登记的停止原因(原文):Principal Investigator has moved to another institution
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-06-21
A Study of Oral L-citrulline in Sickle Cell Disease
编号:NCT02659644登记状态:入组前撤回企业 / 申办者:University of Mississippi Medical Center
药物 / 成分:Oral L-citrulline
登记的停止原因(原文):Principal Investigator moved to another institution
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-06-21
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer
编号:NCT03123744登记状态:入组前撤回企业 / 申办者:Razelle Kurzrock, MD
药物 / 成分:Palbociclib 125mg
登记的停止原因(原文):No study funding available.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-06-18
Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children
编号:NCT01658891登记状态:入组前撤回企业 / 申办者:Chiesi Farmaceutici S.p.A.
药物 / 成分:combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg、free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-06-18
Minocycline Administration During Human Liver Transplantation
编号:NCT02712775登记状态:入组前撤回企业 / 申办者:Medical University of South Carolina
药物 / 成分:Minocycline (yes/no)、Placebo
登记的停止原因(原文):Study logistics
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-06-18
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
编号:NCT03149159登记状态:入组前撤回企业 / 申办者:Medical University of South Carolina
药物 / 成分:Nivolumab、Ipilimumab、Steriotactic radiation therapy
登记的停止原因(原文):This study is withdrawn due to feasibility issues.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-06-15
Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
编号:NCT02702960登记状态:入组前撤回企业 / 申办者:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
药物 / 成分:living related donor partial liver transplantation、Total body irradiation、Bone marrow transplant from same donor、Cyclophosphamide
登记的停止原因(原文):This study was withdrawn due to lack of necessary resources from the liver transplant surgical group.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-06-14
Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab
编号:NCT03059277登记状态:入组前撤回企业 / 申办者:Southeast Clinical Research Associates, LLC
药物 / 成分:Intravitreal Aflibercept
登记的停止原因(原文):Site investigator decided to not move forward with study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-06-14
Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers
编号:NCT03077477登记状态:入组前撤回企业 / 申办者:Aminex Therapeutics, Inc.
药物 / 成分:AMXT 1501、Placebo Oral Tablet
登记的停止原因(原文):Change in FDA required patient population decision prior to study start, new protocol developed, this protocol withdrawn
查看官方原始记录 ↗